Tumor-secreted extracellular vesicles counteract therapy response by triggering inflammatory mesenchymal stem cell development.

Crescenzo Massaro Hilal N Sensoy Manon Mulders Celine De Schrijver Cristina Gómez-Martin Juan Simon-Nieto Tonny Lagerweij Alisha Atmopawiro Jennifer Pérez-Boza Maarten P Bebelman Leontien Bosch Simone Foderaro Mafalda Neves Ferreira Monique A J van Eijndhoven Jan R T van Weering Carmela Dell'Aversana Lucia Altucci C Dilara Savci-Heijnink Niels W C J van de Donk Cristina Giorgio Laura Brandolini Marcello Allegretti Dirk Michiel Pegtel S Rubina Baglio

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Our observations establish iMSCs as major contributors to drug resistance, reveal EVs as physiological triggers of iMSC development and highlight a promising combination strategy to improve therapy response in bone cancer patients.

Keyphrases

mesenchymal stem cells
bone marrow
bone mineral density
stem cells
cell therapy
genome wide
single cell
soft tissue
postmenopausal women